The short version
Sun Pharmaceutical agreed in April 2026 to buy Organon for $14.00 a share in cash, a deal Organon shareholders approved in July. The stock trades at $13.76 today, meaning the market is pricing in a small but real chance the deal falls apart before it closes in early 2027. The filed numbers underneath the acquisition price tell a story of a company that was already cheap on revenue but whose earnings collapsed in 2025, making the multiple look distorted in both directions at once. The open question is whether the deal closes on schedule, because if it does, the math is settled; if it doesn’t, the math gets complicated fast.
Born Carrying the Bag
Organon didn’t choose its balance sheet. When Merck completed the spin-off on June 2, 2021, it handed the new company $9.5 billion in debt and sent nearly as much cash back to itself. That is the original sin of this story: Organon started life as an independent company already carrying a debt load larger than its entire annual revenue, before it had sold a single pill on its own. The business it inherited, a portfolio of women’s health drugs, biosimilars, and older branded medicines, was steady but not growing. Steady and indebted is a hard combination to sell to investors.
For the first three years, the company held together. Revenue in fiscal 2023 was $6.3 billion, growing about 1%, and net margins sat near 16%. Then 2025 arrived and something broke. Full-year 2025 revenue fell to $6.2 billion, net income collapsed to $187 million, and the net margin dropped to 3%. Earnings per share fell more than 80% in two years. That is the collapsed denominator behind the strange-looking price-to-earnings ratio our data shows: a trailing P/E near 19 times is not richness, it is a trough artifact, the same way a car’s fuel gauge reads empty right after you’ve burned through a tank.
What the Crowd Was Doing While the Numbers Fell
Here is the contrast that should not exist: the stock is up nearly half its value over the past six months, and the analyst consensus as of October 13, 2026 is “Reduce” or “Hold,” with an average analyst valuation well below where the stock trades. A stock rising sharply while analysts say sell is not a contradiction; it is a crowd that figured out something the ratings hadn’t caught up to. That something was the acquisition.
Sun Pharmaceutical announced a definitive agreement on April 26, 2026, to buy Organon for $14.00 per share in cash, implying an enterprise value of $11.75 billion. Organon shareholders approved the deal in July 2026. Sun Pharma’s managing director, Kirti Ganorkar, described the acquisition as a “logical next step in strengthening Sun Pharma’s global business.” Organon’s executive chair, Carrie Cox, called it “compelling and immediate value to Organon stockholders.” The deal is expected to close in early 2027, according to World Pharma Today, citing it as the largest biopharma deal of 2026.
The gap between today’s price and $14.00 is about 1.7%. In deal terms, that gap is the market’s estimate of the probability the transaction fails, discounted for the time value of waiting. That gap reflects the market’s collective estimate of execution risk, a figure readers can weigh against their own assessment of deal-close probability.
What the Filed Numbers Actually Show
Strip away the acquisition and the picture is a business generating real cash but carrying a debt load that made equity ownership uncomfortable. The Q2 2026 10-Q filed July 31 shows total debt of $8.55 billion against cash of $1.13 billion, leaving net debt of roughly $7.4 billion. The adjusted EBITDA for full-year 2025 was $1.91 billion, per the company’s own earnings release. That means the company owed, in net debt terms, nearly four years of its own operating earnings. A household carrying four years of take-home pay in debt can service it, but has very little room for anything to go wrong.
Something did go wrong. The Dermavant acquisition in September 2024 added cost and complexity. An endometriosis drug, OG-6219, failed its Phase 2 study in July 2025 and was discontinued. The dividend, which started at $0.28 per quarter in 2021, was cut to $0.02 per quarter in February 2026 to free up cash for debt reduction. That cut is the clearest signal management sent about where the pressure was: paying shareholders less so the lenders could be paid more.
Q2 2026 revenue came in at $1.56 billion, down modestly from the same quarter a year earlier, and net income fell roughly a quarter to $108 million, per the Q2 2026 filing. The company’s own February 2026 guidance, now suspended because of the pending acquisition, had anticipated the full year running essentially flat with 2025. Organon has cancelled its earnings calls while the deal is pending, so Q3 2026 results, expected around November 9, will arrive as a filing rather than a presentation.
The Zone This Stock Lives In
Our data shows Organon’s price-to-sales ratio at 0.6 times, below its own decade median and sitting at the 35th percentile of its own history. On revenue, the stock is modestly cheap relative to its own past. On earnings, the trailing multiple is meaningless because the denominator collapsed. The mood, what the market is actually paying, reflects neither of those readings. It reflects $14.00, the acquisition price, minus a small discount for execution risk.
This is what makes Organon an unusual case for the crowd-study lens. The crowding here is not in a sector chasing a growth story. It is concentrated around the acquisition price, market participants appear to be pricing the probability of deal closure, with the spread between current price and $14.00 reflecting that uncertainty in either direction. The MarketBeat consensus average analyst valuation of $11.40 is essentially the “deal fails” scenario, which is where analysts who don’t model the acquisition as a certainty land. The distance between that valuation and the $14.00 deal price represents the full range of analytical disagreement about deal-close probability.
On the pipeline side, there are real assets: the biosimilar TOFIDENCE received expanded FDA approval in June 2026, and the FDA accepted a supplemental application in September 2026 to extend the approved duration of Organon’s hormone-free IUD, MIUDELLA. These matter more to Sun Pharma’s strategic rationale than to the near-term price, which is now almost entirely a function of deal timing.
Reading the numbers
- $13.76 vs $14.00: The stock price versus the agreed acquisition price. The 1.7% gap reflects the market’s collective estimate of deal-break risk embedded in the current price, the standard mechanism by which pending-acquisition targets trade at a discount to their deal price until closing.
- $8.55 billion in total debt, $1.13 billion in cash (Q2 2026 filing): Net debt of roughly $7.4 billion against annual operating earnings near $1.9 billion means the company owes about four years of earnings to its lenders. Think of a small business earning $50,000 a year carrying $200,000 in loans: serviceable, but every dollar of margin matters.
- EPS $3.99 in 2023 vs $0.72 in 2025 (10-K filings): Earnings per share fell by about 80% in two years. This is why the trailing P/E of 19 times looks alarming but isn’t: the denominator shrank, not the price. A bakery that normally earns $10,000 a month but had a terrible year at $1,800 would look “expensive” on a trailing basis even if its ovens still work.
- Adjusted EBITDA margin of 30.7% in 2025 (company earnings release): EBITDA margin is what’s left of each dollar of sales after operating costs but before interest, taxes, and accounting charges. At 30 cents on the dollar, the underlying business generates real cash. The problem is that much of it goes to service the debt before equity holders see anything.
- $11.40 analyst consensus valuation vs $14.00 deal price: The gap between these two numbers is the entire analytical debate. Analysts who treat the deal as uncertain land near $11.40. Investors who treat it as probable land near $13.76. The filed fundamentals, on their own, would put the stock somewhere in between.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2023 (SEC EDGAR)
- Organon Q4 and Full-Year 2025 Results (Organon.com)
- Sun Pharma Definitive Agreement Announcement (Organon.com)
- Organon Cancels Q1 Earnings Call (Organon.com)
- Sun Pharma / Organon Deal Coverage (World Pharma Today)
- MarketBeat Analyst Consensus, October 13, 2026
- MarketBeat OGN Analyst Valuation and Forecast
- Merck Spin-Off Completion Announcement
